Does Bupropion Cause Weight Loss? Honest Evidence Review

Yes, bupropion can cause modest weight loss — but the magnitude is small and the drug is not FDA-approved for obesity as a single agent. In the largest dedicated trial, Anderson 2002^[1] (a 48-week double-blind RCT of bupropion SR 300–400 mg/day plus a 500-kcal deficit diet), the active-drug arm lost about 7.2–10.1% of body weight vs 5.0% on placebo. Most real-world patients on bupropion for depression lose considerably less — on the order of 1.5 to 3 kg over 6–12 months without a structured calorie deficit. The FDA-approved bupropion-containing obesity drug is Contrave (naltrexone 32 mg + bupropion 360 mg ER), which produced −6.1% body weight at 56 weeks in COR-I^[4]. For magnitude context: semaglutide (Wegovy) produced −14.9% at 68 weeks in STEP-1^[5] and tirzepatide (Zepbound) produced −20.9% at 72 weeks in SURMOUNT-1^[6]. Bupropion is a real but modest tool, with meaningful safety constraints. Here is the verified evidence.

The honest summary

• Bupropion is a norepinephrine and dopamine reuptake inhibitor (NDRI). It is FDA-approved for major depressive disorder, seasonal affective disorder, and smoking cessation (as Zyban) — not as a single agent for obesity.
• As a single agent at 300–400 mg/day, bupropion produces roughly −1.5 to −3 kg over 6–12 months in real-world depression treatment, and larger effects (~5–10% body weight) in dedicated weight-loss trials that combined the drug with a structured caloric deficit (Anderson 2002^[1], Jain 2002^[3], Gadde 2001^[2]).
• Contrave (naltrexone 8 mg + bupropion 90 mg per tablet, maintenance 32 mg / 360 mg total daily) is the FDA-approved bupropion-containing combination for chronic weight management. COR-I (Greenway 2010 Lancet^[4]) reported −6.1% body weight at 56 weeks vs −1.3% on placebo.
• Both bupropion and Contrave carry an FDA boxed warning for suicidal thoughts and behaviors in children, adolescents, and young adults — an antidepressant-class warning. Contraindications include seizure disorders, current or prior diagnosis of bulimia or anorexia nervosa, abrupt discontinuation of alcohol or sedatives, and concurrent or recent (within 14 days) MAOI use.
• Compared with FDA-approved GLP-1 obesity pharmacotherapy, bupropion's effect is modest: STEP-1 reported −14.9% on semaglutide^[5] and SURMOUNT-1 reported −20.9% on tirzepatide^[6].
• Weight regain after stopping bupropion is poorly studied but expected, because the mechanism (appetite and reward modulation) is dose-dependent and does not produce structural metabolic change.

Mechanism: dopamine, norepinephrine, and the reward pathway

Bupropion (originally Wellbutrin, generic since 2006) is a norepinephrine and dopamine reuptake inhibitor — it blocks the transporters that clear those two neurotransmitters from the synapse, increasing their signaling. This is mechanistically distinct from SSRIs (which act on serotonin) and SNRIs (which act on norepinephrine and serotonin). The downstream consequences relevant to body weight are three:

1. Hypothalamic POMC stimulation. Norepinephrine and dopamine modulate firing of pro-opiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus. POMC neurons release alpha-melanocyte-stimulating hormone (α-MSH), which activates MC4R receptors and signals satiety. This is the appetite-suppression mechanism.
2. Reward-pathway modulation. Increased dopaminergic tone in the mesolimbic pathway dampens the reward salience of highly palatable food (sugar, fat) for some patients. This is the “food noise” mechanism patients sometimes describe on bupropion — food becomes less pre-occupying.
3. Mild stimulant effect. Bupropion has weak stimulant-like properties (it is structurally related to cathinone). Patients commonly report increased energy and mild appetite suppression, particularly in the first 4–8 weeks of treatment.

None of these is a structural metabolic intervention. The drug works while it is in the system. Stop the drug, and the signaling returns to baseline within days.

Average weight loss magnitude as a single agent

Three dedicated bupropion-for-obesity trials anchor the single-agent evidence base:

Anderson 2002 Obes Res^[1] — the largest and methodologically strongest. A 48-week double-blind placebo-controlled trial randomized 327 overweight and obese adults to bupropion SR 300 mg/day, 400 mg/day, or placebo, all combined with a 500-kcal/day deficit diet. At 24 weeks (the primary endpoint), the 300 mg and 400 mg arms had lost roughly 7.2% and 10.1% of body weight, respectively, versus 5.0% on placebo (active diet group). Effects were sustained through 48 weeks in the open-label extension.

Gadde 2001 Obes Res^[2] — an earlier, smaller study (n=50 overweight and obese women) of bupropion SR vs placebo over 8 weeks with concomitant caloric restriction. The bupropion arm lost about 4.9% of baseline weight (mean ± SD ~4.9% ± 3.4%) vs ~1.3% on placebo.

Jain 2002 Obes Res^[3] — a 26-week trial in obese patients with depressive symptoms (n=213). Bupropion SR 300–400 mg/day produced a mean weight change of about −4.4 kg (4.6%) vs −1.7 kg on placebo. Notably, depression scores improved as well — the weight effect was not contingent on depression remission.

Three caveats apply to all three trials:

1. They combined bupropion with a structured caloric deficit diet. The drug-alone effect is smaller. Real-world depression treatment (no deficit prescribed) typically yields 1.5–3 kg over 6–12 months.
2. Sample sizes are modest (n=50 to n=327). These are not STEP-scale trials.
3. The 300–400 mg/day weight-loss dose is at the upper end of the standard antidepressant dose range. The 150 mg/day dose used for smoking cessation produces minimal weight effect.

Contrave: bupropion + naltrexone for FDA-approved obesity care

Contrave (Currax Pharmaceuticals) was FDA-approved in September 2014 as the first fixed-dose combination of two existing generic medications for chronic weight management. Each tablet contains naltrexone HCl 8 mg + bupropion HCl 90 mg ER. Maintenance dose is 2 tablets twice daily = 32 mg naltrexone + 360 mg bupropion per day. The combination rationale is mechanistic: bupropion stimulates POMC neurons, but the α-MSH released also activates a beta-endorphin feedback loop that brakes further POMC firing. Naltrexone (an opioid receptor antagonist) blocks that brake, sustaining the appetite-suppression signal.

COR-I (Greenway 2010 Lancet, PMID 20673995)^[4] was the pivotal phase 3 trial. The multicentre, randomised, double-blind, placebo-controlled trial randomized 1,742 overweight or obese adults (BMI 30–45, or 27–45 with comorbidity) to naltrexone 16 mg + bupropion 360 mg, naltrexone 32 mg + bupropion 360 mg, or placebo, all on a mild caloric deficit diet plus behavioral modification. At week 56, the 32/360 arm (the approved Contrave dose) had lost 6.1% of body weight vs 1.3% on placebo (p<0.0001), and 48% of Contrave patients achieved ≥5% weight loss vs 16% on placebo. The most common adverse reaction was nausea (32.5% on Contrave vs 6.7% placebo per the FDA label^[8]).

Contrave's 6.1% sits between single-agent bupropion (real-world ~2–3% off-trial; ~5–10% on-trial with diet) and the FDA-approved GLP-1 medications. It is a real option for patients who cannot tolerate GLP-1 nausea, cannot afford GLP-1 cash-pay pricing, or have a contraindication to GLP-1 therapy — not for patients seeking the largest possible weight effect.

Magnitude comparison: bupropion vs the FDA-approved obesity drugs

The Anderson 2002 numbers should be read with care. They represent the upper bound of what bupropion can do in a clinical-trial setting with a 500-kcal deficit diet and weekly behavioral support. Patients prescribed bupropion 300 mg/day for depression in routine practice typically lose substantially less — on the order of 1.5–3 kg over a year, sometimes none. The drug is not a substitute for the calorie deficit. It can make the deficit easier to maintain.

FDA boxed warning: suicidal thoughts and behaviors

Bupropion and all bupropion-containing products (Wellbutrin, Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL, Contrave) carry an FDA boxed warning — the most serious warning the FDA issues — for suicidal thoughts and behaviors in children, adolescents, and young adults (under age 25). This is the antidepressant-class warning, not a bupropion-specific finding, and it applies to all antidepressants regardless of mechanism.

Per the Wellbutrin XL label^[7] and the Contrave label^[8]:

• Patients of all ages should be monitored for clinical worsening, suicidality, or unusual changes in behavior, particularly during the first few months of therapy or at dose changes.
• Families and caregivers should be advised of the need for close observation.
• Bupropion is not approved for use in pediatric patients.
• The warning applies to all indications — depression, smoking cessation, weight management — not only to psychiatric use.

The practical consequence is that bupropion and Contrave are not appropriate first-line options for adults with active suicidal ideation, recent suicide attempt, or untreated bipolar disorder — populations where GLP-1 pharmacotherapy is also not a first-line behavioral fix. Behavioral assessment and a baseline PHQ-9 are reasonable before starting either drug.

Contraindications

Bupropion and Contrave share a set of absolute contraindications drawn from bupropion's pharmacology. Prescribers must rule these out before starting:

• Seizure disorder. Bupropion lowers the seizure threshold in a dose-dependent fashion. Patients with a current or past seizure disorder should not take bupropion-containing products.
• Current or prior diagnosis of bulimia or anorexia nervosa. Patients with eating disorders have an elevated baseline seizure risk on bupropion (driven by electrolyte abnormalities and low body weight). This is a hard contraindication on every bupropion label.
• Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or other sedatives. Withdrawal lowers the seizure threshold further; bupropion compounds the risk.
• Concurrent or recent (within 14 days) use of MAOIs. Risk of hypertensive crisis. This includes irreversible MAOIs (phenelzine, tranylcypromine) and the reversible MAOI selegiline at antidepressant doses.
• Hypersensitivity to bupropion.
• Concurrent use of another bupropion-containing product. Stacking Wellbutrin XL with Contrave or Zyban exceeds the cumulative dose ceiling and dramatically raises seizure risk.
• For Contrave specifically: chronic opioid use, opioid agonist therapy (methadone, buprenorphine), or acute opioid withdrawal — naltrexone precipitates withdrawal. Uncontrolled hypertension is also a Contrave contraindication.

Comparison vs GLP-1 receptor agonists

The clean comparison: a 100-kg patient at trial endpoint.

• Bupropion 300 mg/day alone: ~−7 kg on-trial with a structured deficit (Anderson 2002^[1]); typically −1.5 to −3 kg in routine depression treatment without a prescribed deficit.
• Contrave 32/360 mg/day: ~−6 kg at 56 weeks (COR-I^[4]).
• Wegovy (semaglutide 2.4 mg): ~−15 kg at 68 weeks (STEP-1^[5]).
• Zepbound (tirzepatide 15 mg): ~−21 kg at 72 weeks (SURMOUNT-1^[6]).

The GLP-1 medications produce 2–4x the weight effect of Contrave and 5–10x the effect of routine bupropion. The trade-off is cost (GLP-1 cash-pay typically $300–$1,300/month vs generic bupropion <$50/month and brand Contrave $99–$199/month on the LillyDirect- style direct-to-patient programs), tolerability (GLP-1 nausea ~40% vs Contrave nausea ~33%; the symptom profiles differ), and the boxed-warning landscape (only bupropion- containing products carry the suicidality warning; the GLP-1 labels do not as of February 2026 per the FDA Drug Safety Communication).

Bupropion or Contrave is a reasonable choice for patients who:

• Cannot tolerate GLP-1 GI side effects.
• Have a co-occurring depression or smoking-cessation indication where bupropion is independently appropriate (this is the most common real-world use case).
• Have an insurance plan that excludes weight-loss GLP-1 coverage but covers bupropion or Contrave (a common state-Medicaid pattern).
• Want a lower monthly cost.

It is not a reasonable choice for patients with a seizure disorder, an active eating disorder, current MAOI use, or active opioid agonist therapy (Contrave specifically).

Weight regain after stopping

Bupropion does not produce structural metabolic change. It modulates dopamine and norepinephrine signaling while it is in the system. There are no published dedicated trials of weight trajectory after planned bupropion discontinuation in a weight-management population.

The expected pattern, by analogy with other appetite-modulating drugs and with the GLP-1 literature (STEP-1 extension published as STEP-4 reported regain of about two-thirds of lost weight in the year after semaglutide withdrawal), is that any weight lost on bupropion as a single agent will gradually return unless the behavioral and dietary changes that accompanied treatment are sustained. Contrave is intended for chronic use; the FDA label does not specify a treatment ceiling. Bupropion for depression is similarly intended for chronic use as clinically indicated.

Bottom line

• Bupropion does cause modest weight loss. The published single-agent trials report 5–10% body weight when paired with a structured deficit diet (Anderson 2002^[1], Gadde 2001^[2], Jain 2002^[3]); routine real-world depression treatment typically yields 1.5–3 kg over a year.
• The FDA-approved bupropion-containing obesity drug is Contrave (naltrexone 8 mg + bupropion 90 mg per tablet), which produced −6.1% body weight at 56 weeks in COR-I^[4].
• Both carry an FDA boxed warning for suicidal thoughts in patients under 25 (antidepressant-class warning) and are contraindicated in seizure disorder, bulimia or anorexia nervosa, and concurrent MAOI use.
• Compared with GLP-1 obesity pharmacotherapy — semaglutide −14.9%^[5] and tirzepatide −20.9%^[6] — bupropion is a modest tool. It earns its place for patients who cannot tolerate GLP-1 therapy, have a co-occurring depression or smoking-cessation indication, or face a cost or coverage barrier to GLP-1 access.
• Weight regain after stopping is expected, because the drug does not produce structural metabolic change.

Related research and tools

• Wellbutrin XL for weight loss: how fast and how much? — the brand-Wellbutrin-XL-specific deep dive, with the FDA-label adverse-reactions table breakdown
• Contrave (naltrexone + bupropion) evidence review — the FDA-approved combination, COR-I −6.1% context, prior authorization landscape
• Antidepressants, weight, and GLP-1s — the full SSRI / SNRI / NDRI weight-effect map, Gafoor 2018 BMJ cohort, drug-by-drug breakdown
• Semaglutide overview and tirzepatide overview — the FDA-approved GLP-1 medications with the larger weight-loss magnitude for context
• GLP-1 protein calculator — the protein target for lean-mass preservation on any appetite-suppressing medication (1.6–2.0 g/kg)

Important disclaimer. This article is educational and does not constitute medical advice. Bupropion and Contrave are prescription medications with an FDA boxed warning for suicidal thoughts and behaviors in patients under 25 and meaningful contraindications (seizure disorder, bulimia or anorexia nervosa, MAOI use, abrupt sedative withdrawal). Patients considering bupropion or Contrave for any reason — depression, smoking cessation, or weight management — should discuss the indication and the contraindication checklist with a prescribing clinician. PMIDs were independently verified against the PubMed E-utilities API on 2026-05-28. FDA-label quotations and Adverse Reactions data were taken from DailyMed on the same date. The COR-I numbers reflect the 32 mg naltrexone / 360 mg bupropion arm at week 56 in the modified-intent-to-treat analysis as reported in the Lancet primary publication.

Last verified: 2026-05-28. Next review: every 12 months, or sooner if new RCT evidence on bupropion or Contrave is published, or if the FDA boxed warning or contraindication list materially changes.